Search

Your search keyword '"Calo', Lorenzo"' showing total 242 results
Start Over Author "Calo', Lorenzo"
242 results on '"Calo', Lorenzo"'

2. Diagnosis and management of Bartter syndrome: executive summary of the consensus and recommendations from the European Rare Kidney Disease Reference Network Working Group for Tubular Disorders

Author

Konrad, Martin, Nijenhuis, Tom, Ariceta, Gema, Bertholet-Thomas, Aurelia, Calo, Lorenzo A., Capasso, Giovambattista, Emma, Francesco, Schlingmann, Karl P., Singh, Mandeep, Trepiccione, Francesco, Walsh, Stephen B., Whitton, Kirsty, Vargas-Poussou, Rosa, and Bockenhauer, Detlef

Published
2021
Full Text
View/download PDF

13. Parathyroid hormone and phosphate homeostasis in patients with Bartter and Gitelman syndrome: an international cross-sectional study

Author

Verploegen, Maartje F. A., Vargas-Poussou, Rosa, Walsh, Stephen B., Alpay, Harika, Amouzegar, Atefeh, Ariceta, Gema, Atmis, Bahriye, Bacchetta, Justine, Barany, Peter, Baron, Stephanie, Bayrakci, Umut Selda, Belge, Hendrica, Besouw, Martine, Blanchard, Anne, Bokenkamp, Arend, Boyer, Olivia, Burgmaier, Kathrin, Calo, Lorenzo A., Decramer, Stephane, Devuyst, Olivier, van Dyck, Maria, Ferraro, Pietro Manuel, Fila, Marc, Francisco, Telma, Ghiggeri, Gian Marco, Gondra, Leire, Guarino, Stefano, Hooman, Nakysa, Hoorn, Ewout J., Houillier, Pascal, Kamperis, Konstantinos, Kari, Jameela A., Konrad, Martin, Levtchenko, Elena, Lucchetti, Laura, Lugani, Francesca, Marzuillo, Pierluigi, Mohidin, Barian, Neuhaus, Thomas J., Osman, Abdaldafae, Papizh, Svetlana, Perello, Manel, Rookmaaker, Maarten B., Conti, Valerie Said, Santos, Fernando, Sawaf, Ghalia, Serdaroglu, Erkin, Szczepanska, Maria, Taroni, Francesca, Topaloglu, Rezan, Trepiccione, Francesco, Vidal, Enrico, Wan, Elizabeth R., Weber, Lutz, Yildirim, Zeynep Yuruk, Yuksel, Selcuk, Zlatanova, Galia, Bockenhauer, Detlef, Emma, Francesco, Nijenhuis, Tom, Verploegen, Maartje F. A., Vargas-Poussou, Rosa, Walsh, Stephen B., Alpay, Harika, Amouzegar, Atefeh, Ariceta, Gema, Atmis, Bahriye, Bacchetta, Justine, Barany, Peter, Baron, Stephanie, Bayrakci, Umut Selda, Belge, Hendrica, Besouw, Martine, Blanchard, Anne, Bokenkamp, Arend, Boyer, Olivia, Burgmaier, Kathrin, Calo, Lorenzo A., Decramer, Stephane, Devuyst, Olivier, van Dyck, Maria, Ferraro, Pietro Manuel, Fila, Marc, Francisco, Telma, Ghiggeri, Gian Marco, Gondra, Leire, Guarino, Stefano, Hooman, Nakysa, Hoorn, Ewout J., Houillier, Pascal, Kamperis, Konstantinos, Kari, Jameela A., Konrad, Martin, Levtchenko, Elena, Lucchetti, Laura, Lugani, Francesca, Marzuillo, Pierluigi, Mohidin, Barian, Neuhaus, Thomas J., Osman, Abdaldafae, Papizh, Svetlana, Perello, Manel, Rookmaaker, Maarten B., Conti, Valerie Said, Santos, Fernando, Sawaf, Ghalia, Serdaroglu, Erkin, Szczepanska, Maria, Taroni, Francesca, Topaloglu, Rezan, Trepiccione, Francesco, Vidal, Enrico, Wan, Elizabeth R., Weber, Lutz, Yildirim, Zeynep Yuruk, Yuksel, Selcuk, Zlatanova, Galia, Bockenhauer, Detlef, Emma, Francesco, and Nijenhuis, Tom

Abstract

Background Small cohort studies have reported high parathyroid hormone (PTH) levels in patients with Bartter syndrome and lower serum phosphate levels have anecdotally been reported in patients with Gitelman syndrome. In this cross-sectional study, we assessed PTH and phosphate homeostasis in a large cohort of patients with salt-losing tubulopathies. Methods Clinical and laboratory data of 589 patients with Bartter and Gitelman syndrome were provided by members of the European Rare Kidney Diseases Reference Network (ERKNet) and the European Society for Paediatric Nephrology (ESPN). Results A total of 285 patients with Bartter syndrome and 304 patients with Gitelman syndrome were included for analysis. Patients with Bartter syndrome type I and II had the highest median PTH level (7.5 pmol/L) and 56% had hyperparathyroidism (PTH >7.0 pmol/L). Serum calcium was slightly lower in Bartter syndrome type I and II patients with hyperparathyroidism (2.42 versus 2.49 mmol/L; P = .038) compared to those with normal PTH levels and correlated inversely with PTH (r(s) -0.253; P = .009). Serum phosphate and urinary phosphate excretion did not correlate with PTH. Overall, 22% of patients had low serum phosphate levels (phosphate-standard deviation score < -2), with the highest prevalence in patients with Bartter syndrome type III (32%). Serum phosphate correlated with tubular maximum reabsorption of phosphate/glomerular filtration rate (TmP/GFR) (r(s) 0.699; P < .001), suggesting renal phosphate wasting. Conclusions Hyperparathyroidism is frequent in patients with Bartter syndrome type I and II. Low serum phosphate is observed in a significant number of patients with Bartter and Gitelman syndrome and appears associated with renal phosphate wasting.

Published
2022

17. Potential role of phytochemicals in metabolic syndrome prevention and therapy

Author

FRANCINI PESENTI, Francesco, Spinella, Paolo, and Calo', Lorenzo

Subjects
cardiovascular risk, bioactive substances, nutrition, Review, metabolic syndrome
Abstract

Metabolic syndrome (MetS) is a set of cardiovascular risk factors which severely increases the risk of type II diabetes, renal disease and cardiovascular disease. Over the last decades, the role of dietary bioactive substances in features of MetS has been extensively investigated. Due to their multiple properties, these plant-derived natural compounds have demonstrated to provide positive effects in obesity, diabetes, renal and in cardiovascular disease. Catechins of green tea and caffeine reduce body mass index and waist circumference. Catechins, anthocyanins and proanthocyanidins of cocoa reduce blood pressure and blood glucose. Curcumin and silymarin exert hepatoprotective effects. Monacolins of red yeast rice are effective cholesterol-lowering agents. However, inconsistent or conflicting results have been found in clinical trials when other promising compounds in vitro or in animal studies, such as policosanol, curcumin or silymarin, were used. Low oral bioavailability of substances, ineffective dosages, inadequate treatment duration and insufficient statistical approach may explain the lack of effectiveness observed in some human studies. Further clinical studies are needed to better understand the role of bioactive compounds in the prevention and management of MetS.

Published
2019

24. Walnuts reduce aortic ET-1 mRNA levels in hamsters fed a high-fat, atherogenic diet

Author

Davis, Paul, Valacchi, Giuseppe, Pagnin, Elisa, Shao, Qiming, Gross, Heidrun B., Calo, Lorenzo, and Yokoyama, Wallace

Subjects
Walnut -- Nutritional aspects, Walnut -- Research, Coronary heart disease -- Risk factors, Coronary heart disease -- Research, Food/cooking/nutrition
Abstract

Walnut consumption is associated with reduced coronary vascular disease (CVD) risk; however, the mechanisms responsible remain incompletely understood. Recent clinical studies suggested that these mechanisms involve nonplasma lipid--related effects on endothelial function. Male Golden Syrian hamsters (12 groups, n = 10-15) were fed for 26 wk atherosclerotic, high-fat, hyperlipidemic diets with increasing concentrations of whole walnuts (61-150 g/kg diet), or [alpha]-tocopherol ([alpha]-T, 8.1-81 mg/kg diet) and single diets with either walnut oil (32g/kg diet) or pure [alpha]-tocopherol ([gamma]-T; 81 mg/kg diet) added. Aortic endothelin 1 (ET-1), an important endothelial regulator, was assayed as mRNA. Aortic cholesterol ester (CE) concentration along with other vascular stress markers (Cu/Zn and Mn superoxide dismutase, biliverdin reductase) and plasma lipid concentrations were determined. Hyperlipidemia (plasma LDL cholesterol ~6 times normal) occurred in ali groups. Aortic CE concentration, a measure of atherosclerotic plaque, was highest in the lowest [alpha]-T only group and declined significantly with increasing [alpha]-T. The aortic CE of all walnut groups was decreased significantly relative to the lowest [alpha]-T only group but showed no dose response. The diets did not produce changes in the other vascular stress markers, whereas aortic ET-1 mRNA levels declined dramatically with increasing dietary walnuts (to a 75% reduction in the highest walnut content group compared with the lowest [alpha]-T group) but were unaltered in the [alpha]-T groups or [gamma]-T group. The study results are consistent with those of human walnut feeding studies and suggest that the mechanisms underlying those results are mediated in part by ET-1--dependent mechanisms. The contrasting results between the [alpha]-tocopherol or [gamma]-tocopherol diets and the walnut diets also make it unlikely that the nonplasma lipid-related CVD effects of walnuts are due to their [alpha]-tocopherol or [gamma]-tocopherol content. Finally, the results indicate that the walnut fat compartment is a likely location for the components responsible for the reduced aortic CE concentration. KEY WORDS: * walnuts * endothelin * hamsters * tocopherol * atherosclerosis

Published
2006

29. Research update for articles published in EJCI in 2008

Author

Anderwald, Christian, Ankersmit, Hendrik J., Badaoui, Abdenor, Beneduce, Luca, Buko, Vyacheslav U., Calo, Lorenzo A., Carrero, Juan J., Chang, Chun-Yi, Chang, Kuo-Chu, Chen, Yi-Jen, Cnotliwy, Miloslaw, Costelli, Paola, Crujeiras, Ana B., Cuocolo, Alberto, Davis, Paul A., de Boer, Onno J., Ebenbichler, Christoph F., Erridge, Clett, Fassina, Giorgio, Felix, Stephan B., García-Gómez, María C., Guerrero-Romero, Fernando, Haider, Dominik G., Heinemann, Akos, Herda, Lars R., Hoogeveen, Ellen K., Hörl, Walter H., Iglseder, Bernhard, Huang, Kuo-Chin, Kaser, Susanne, Kastrati, Adnan, Kuzniatsova, Nadzeya, Latella, Giovanni, Lichtenauer, Michael, Lin, Yung-Kuo, Lip, Gregory Y. H., Lu, Nong-Hua, Lukivskaya, Oxana, Luschnig, Petra, Maniscalco, Mauro, Martinez, Alfredo J., Müller-Krebs, Sandra, Ndrepepa, Gjin, Nicolaou, Giovanna, Peck-Radosavljevic, Markus, Penna, Fabio, Pintó, Xavier, Reiberger, Thomas, Rodriguez-Moran, Martha, Schmidt, Annette, Schwenger, Vedat, Spinelli, Letizia, Starkel, Peter, Stehouwer, Coen D. A., Stenvinkel, Peter, Strasser, Peter, Suzuki, Hiroshi, Tschoner, Alexander, van der Wal, Allard C., Vesely, David L., Wen, Chiung-Jung, Wiernicki, Ireneusz, Zanninelli, Giuliana, and Zhu, Y.

Published
2010
Full Text
View/download PDF

45. Cigarette Smoking is Associated with Decreased Bone Gla-protein (BGP) Levels in Hemodialysis Patients

Author

Fusaro, Maria, primary, Gallieni, Maurizio, additional, Aghi, Andrea, additional, Iervasi, Giorgio, additional, Rizzo, Maria A., additional, Stucchi, Andrea, additional, Noale, Marianna, additional, Tripepi, Giovanni, additional, Nickolas, Thomas, additional, Veronese, Nicola, additional, Fabris, Fabrizio, additional, Giannini, Sandro, additional, Calo, Lorenzo, additional, Piccoli, Antonio, additional, Mereu, Maria C., additional, Cosmai, Laura, additional, Ferraro, Alberto, additional, Magonara, Fiorenza, additional, Spinello, Michela, additional, Sella, Stefania, additional, and Plebani, Mario, additional

Published
2018
Full Text
View/download PDF

46. Insulin signaling, glucose metabolism, and the angiotensin II signaling system: studies in Bartter's/Gitelman's syndromes

Author

Davis, Paul A., Pagnin, Elisa, Semplicini, Andrea, Avogaro, Angelo, and Calo, Lorenzo A.

Subjects
Research, Health aspects, Diabetes research -- Health aspects, Glucose metabolism -- Research -- Health aspects, Hormone receptors -- Research -- Health aspects, Insulin -- Health aspects -- Research, Diabetes -- Research
Abstract

Taniyama et al. (1) have recently reported that angiotensin II (Ang II) in vitro decreases insulin receptor substrate-1 protein levels via Src, phosphoinositide-dependent kinase-1, and reactive oxygen species-mediated phosphorylation of [...]

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results